Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo (A01)

Identifying potential tumor drivers through integration of gene expression and DNA copy number in SI-NET (A02)

The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation (A03)

Single-cell transcriptomic analysis of small intestinal neuroendocrine tumors revealed potential mechanisms of mesenteric fibrosis (A04)

Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients (A05)

Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition (A06)

Unravelling the RNA landscape of small intestine neuroendocrine neoplasms applying transcriptomic and spliceosomic perspectives (A09)

Evaluating a possible association between promoter methylation level of genes encoding catecholamine metabolizing enzymes and metanephrine secretion in pheochromocytoma and paraganglioma (A10)

Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis (A11)

Immune landscape of small intestinal neuroendocrine tumor at single-cell level (A12)

Dissecting the intra- and inter-tumor heterogeneity of adrenocortical carcinoma by single-cell multi-omics analyses (A13)

Dissecting the single-cell transcriptome network underlying thymic neuroendocrine tumor and thymus non-malignant tissues (A14)

Characterising the tumor microenvironment of multifocal small intestinal NETs (A15)

Detecting NET using Methylation-based biomarkers and the novel IMPRESS technology (A16)

Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumors in the lungNENomics project (A17)

Transcriptomic and spliceosomic landscapes of pancreatic neuroendocrine tumors generated through Oxford Nanopore Technology sequencing (A18)

Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors (A19)

Prevalence of germline mutations in pancreatic neuroendocrine tumors (A21)

Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms (A22)

Inactivation of PHLDA3 gene leading to tumorigenesis of pancreatic neuroendocrine tumors and its molecular mechanisms (A23)

Germline mutation spectrum of neuroendocrine tumors (A24)

Thoughts on the results of genetic map of a family (A25)

Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors (A27)

Clinical and epidemiological profile of neuroendocrine differentiation – A hospital-based retrospective study (A28)

Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under the pattern of genomic instability and histological grading (A30)

Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy (B01)

Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets (B02)

Establishment of a rat model of diarrhea induced by Surufatinib (B04)

Establishment of novel patient-derived preclinical models for neuroendocrine tumors (B05)

Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis (B06)